Veraxa Biotech AGNASDAQ: VRXA

VERAXA Biotech (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy

· Issued by Veraxa Biotech AG

Summary by 6ix AI

VERAXA Biotech (NASDAQ: VRXA), the subject of an article distributed by IBN on September 16th, 2026, is developing antibody-based cancer therapies built on its proprietary BiTAC concept, with an emphasis on solid tumors.

Key details

  • BiTAC stands for Bi-targeted Tumor-Associated Cytotoxicity. VERAXA says the platform uses two complementary molecules designed to switch on cell-killing activity only when both recognize targets on the same tumor cell.
  • VERAXA is applying BiTAC to antibody-drug conjugates, which are antibodies linked to a drug, and to T-cell engagers, which are antibodies that direct immune T cells toward cancer cells. Its portfolio also includes engineered antibody formats.
  • VERAXA says its aim is to improve the therapeutic window of existing treatments, meaning the range between a dose that works and one that causes harm, by making them more selective.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/veraxa-biotech-nasdaq-vrxa-building-a-new-approach-to-precision-cancer-therapy

Featured Image

Austin, Texas, United States, September 16th, 2026, NewsDirect

  • VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities.
  • Its proprietary BiTAC platform uses two complementary molecules that are designed to activate cytotoxic activity only when both recognize targets on the same tumor cell.
  • The company is applying the BiTAC concept to both antibody-drug conjugates ("ADCs") and T-cell engagers ("TCEs"), with an emphasis on solid tumors.
  • With ADCs and bispecific antibodies attracting substantial investment, VERAXA is operating in oncology markets where technological differentiation can have significant strategic value.

VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a time when oncology research is increasingly focused on a difficult question: how can powerful treatments be made more selective without sacrificing their ability to kill cancer cells? The wiss biotechnology company is approaching that problem through a portfolio of antibody-drug conjugates ("ADCs"), T-cell engagers ("TCEs") and engineered antibody formats. At the center of the strategy is its proprietary BiTAC, or Bi-targeted Tumor-Associated Cytotoxicity, concept.

The objective is not simply to produce another antibody with a new target. VERAXA is attempting to change the...

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA

Corporate Communications

IBN

Austin, Texas

www.IBN.ai

512.354.7000 Office

[email protected]

Contact
IBNwww.InvestorBrandNetwork.com[email protected]

Veraxa Biotech AG on 6ix

Earlier from Veraxa Biotech

Later from Veraxa Biotech

All Veraxa Biotech news releases